Unibest

Pharmaceutical intermediates

Axitinib Intermediates

2 pharmaceutical intermediates for Axitinib. Indication: Renal cell carcinoma.

提交项目All intermediates

About Axitinib

Originator
Pfizer Inc
Indication
Renal cell carcinoma
Approved Date
01/27/2012
DS/DP
04/29/2025

Available intermediates

2 intermediates currently listed for Axitinib. Request specifications, documentation or a quotation for any item below.

Axitinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
6-Iodo-1H-indazole261953-36-0//
(E)-6-Iodo-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)- 1H-indazole886230-77-9//

Other programs under A

AbemaciclibAbrocitinibAcalabrutinibAdagrasibAfatinibAfoxolanerAlectinib HydrochlorideAlfacalcidol

Building toward Axitinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →